Emily Hank
Department für Pharmazie
Ludwig-Maximilians-Universität München
Butenandtstraße 7
D-81377 München
Zi.Nr.: C1.050A
Tel.: +49 (0)89 2180 77927
Fax.: +49 (0)89 2180 77247
Mail: Emily.Hank@cup.lmu.de
Research Interest
TLX (human homologue of Drosophila tailless) is an orphan nuclear receptor that is mainly expressed in neural stem cells. Its link to neurodegenerative diseases and neurological disorders evokes our group’s interest for TLX as a pharmaceutical target. In order to explore the pharmacological potential and the medicinal chemistry of this nuclear receptor, a set of potent and selective tool compounds is needed. My current aim is to perform SAR studies on a recently discovered TLX lead agonist.
Publications
Hank, E. C.; Sai, M.; Kasch, T.; Meijer, I.; Marschner, J. A.; Merk, D. Development of Tailless Homologue (TLX) Agonist Chemical Tools. J. Med. Chem., 2024. DOI
Sai, M.; Hank, E. C.; Lewandowski, M.; Kasch, T.; Marschner, J. A.; Merk, D. Development of Potent and Selective Nurr1 Agonists from Amodiaquine By Scaffold Hopping and Fragment Growing. Commun. Chem., 2024, 7, 149. DOI
Michel, M.; Benítez-Buelga, C.; Calvo, P. A.; Hanna, B. M. F.; Mortusewicz, O.; Masuyer, G.; Davies, J.; Wallner, O.; Sanjiv, K.; Albers, J. J.; Castañeda-Zegarra, S.; Jemth, A.-S.; Visnes, T.; Sastre-Perona, A.; Danda, A. N.; Homan, E. J.; Marimuthu, K.; Zhenjun, Z.; Chi, C. N.; Sarno, A.; Wiita, E.; Nicolai, C. von; Komor, A. J.; Rajagopal, V.; Müller, S.; Hank, E. C.; Varga, M.; Scaletti, E. R.; Pandey, M.; Karsten, S.; Haslene-Hox, H.; Loevenich, S.; Marttila, P.; Rasti, A.; Mamonov, K.; Ortis, F.; Schömberg, F.; Loseva, O.; Stewart, J.; D'Arcy-Evans, N.; Koolmeister, T.; Henriksson, M.; Michel, D.; Ory, A. de; Acero, L.; Calvete, O.; Scobie, M.; Hertweck, C.; Vilotijevic, I.; Kalderén, C.; Osorio, A.; Perona, R.; Stolz, A.; Stenmark, P.; Berglund, U. W.; Vega, M. de; Helleday, T. Small-molecule activation of OGG1 increases oxidative DNA damage repair by gaining a new function. Science, 2022, 376, 1471–1476. DOI
Müller, C.; Hank, E.; Giera, M.; Bracher, F. Dehydrocholesterol Reductase 24 (DHCR24): Medicinal Chemistry, Pharmacology and Novel Therapeutic Options. Curr. Med. Chem., 2022, 29, 4005–4025. DOI